Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21101467 | 0.77 | AR (0.41) | ARHTT | |
| SCHEMBL13072463 | 0.75 | LOXL2 (0.41) | LOXL2GAAHTTRHEBGRIN2D | |
| SCHEMBL17351268 | 0.72 | CSNK2A1 (0.44) | LOXL2GAAHTTRHEBGRIN2D | |
| SCHEMBL10058615 | 0.69 | GHSR (0.43) | LOXL2 | |
| SCHEMBL13624442 | 0.68 | ALOX15 (0.50) | LOXL2 | |
| SCHEMBL2056276 | 0.68 | LOXL2 (0.68) | LOXL2 | |
| SCHEMBL3924867 | 0.67 | GPR35 (0.46) | LOXL2RHEB | |
| SCHEMBL13072465 | 0.67 | CYP2A6 (0.42) | LOXL2GAAHTT | |
| SCHEMBL26422975 | 0.67 | GPR84 (0.38) | LOXL2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8957459 | 0.67 | CSNK2A1 (0.50) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | ROCK1, RHOA, ROCK2 | AR 4478/4885LOXL2 1234/4885GAA 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.